Welcome to our dedicated page for AbbVie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. (ABBV) announced completion of its acquisition of Apogee Therapeutics, Inc. for $135.11 per share in cash, implying a total equity value of approximately $10.9 billion, adding late-stage and early-stage immunology assets focused on atopic dermatitis, asthma and COPD. Apogee is now part of AbbVie.
Apogee’s lead drug candidate zumilokibart (APG777), a half‑life extended IL‑13 monoclonal antibody for atopic dermatitis, showed in a Phase 2 trial that about two‑thirds of patients achieved significant skin clearance at 16 weeks, with sustained control enabling quarterly or twice‑yearly dosing, and a favorable safety profile. Combination candidate APG273, which includes an antibody blocking TSLP, is being developed for asthma with data supporting long‑acting dosing.
AbbVie expects the acquisition to reduce adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032, but is reaffirming its 2026 full‑year adjusted diluted EPS guidance range of $13.87–$14.07 and third‑quarter 2026 adjusted diluted EPS guidance of $3.84–$3.88. The 2026 EPS outlook includes an unfavorable $0.58 per share impact from acquired IPR&D and milestones recorded through the second quarter.
AbbVie Inc. (ABBV) reported insider equity transactions by EVP and Chief Business/Strategy Officer Nicholas Donoghoe on August 14, 2026. Donoghoe exercised employee stock options for 32,710 shares of common stock at an exercise price of $79.02 per share under AbbVie’s 2013 incentive stock program, then sold 32,710 shares of common stock in a separate transaction. The options exercised were from a grant that vested in annual increments between 2020 and 2022 and now show 0 options remaining from this specific grant.
AbbVie Inc. (ABBV) completed an underwritten public offering of multiple series of unsecured, unsubordinated senior notes to help finance its previously announced acquisition of Apogee Therapeutics, Inc. The offering includes $500,000,000 senior floating rate notes due 2028 and eight series of fixed-rate notes.
The fixed-rate series comprise $1,000,000,000 of 4.500% notes due 2028, $1,250,000,000 of 4.650% notes due 2030, $1,500,000,000 of 4.875% notes due 2031, $1,250,000,000 of 5.050% notes due 2033, $1,500,000,000 of 5.300% notes due 2036, $1,000,000,000 of 5.450% notes due 2038, $1,500,000,000 of 6.000% notes due 2056 and $500,000,000 of 6.100% notes due 2066.
The floating rate notes and 4.500% 2028 notes mature on August 18, 2028; the 2030 notes mature on March 15, 2030; all other fixed-rate series mature on September 15 of their stated year. AbbVie expects to use the net proceeds primarily to pay a portion of the cash consideration to Apogee shareholders and related fees, with any remainder for general corporate purposes. If the Apogee acquisition is not pursued or the definitive agreement is terminated, AbbVie must redeem all notes maturing between 2028 and 2038 at 101% of principal plus accrued interest under a special mandatory redemption.
AbbVie Inc. is issuing a total of $10.0 billion of unsecured senior notes in nine series, including $500 million floating rate notes due 2028 and eight fixed-rate tranches maturing between 2028 and 2066 with coupons ranging from 4.500% to 6.100%. The notes rank equally with AbbVie’s existing unsecured senior debt and are structurally subordinated to obligations of its subsidiaries.
AbbVie expects net proceeds of approximately $9.93 billion, to be used to fund a portion of the $10.9 billion cash acquisition of Apogee Therapeutics, related fees, and for general corporate purposes, including potential debt repayment. If the Apogee acquisition is not pursued or the acquisition agreement is terminated, AbbVie must redeem the floating-rate and shorter- to medium-term fixed-rate notes at 101% of principal plus accrued interest, while the 2056 and 2066 notes are excluded from this special mandatory redemption.
As of June 30 2026, AbbVie had $68.4 billion of unsecured senior notes outstanding and, on a pro forma basis including this offering, total indebtedness would be about $80.4 billion. The company also has a $10.0 billion 364-day delayed draw term loan, $8.0 billion of unused revolving credit capacity, and a $2.0 billion term loan due 2027.
AbbVie Inc. entered into an underwriting agreement with Morgan Stanley, BofA Securities, J.P. Morgan and SG Americas for multiple series of senior notes, including senior floating rate notes due 2028 and fixed-rate notes with coupons from 4.500% to 6.100% maturing between 2028 and 2066.
The offering is registered under the Securities Act, with closing expected on August 18, 2026, subject to customary conditions. AbbVie expects approximately $9.93 billion in net proceeds and intends to use them to fund part of its Apogee Therapeutics acquisition, pay related costs, for other general corporate purposes, and the net proceeds will reduce commitments under its $10.0 billion 364-day delayed draw term loan facility.
AbbVie Inc. is conducting a primary offering of multiple series of unsecured senior notes, including floating-rate and fixed-rate tranches, under its effective shelf registration. The notes rank equally with AbbVie’s existing unsecured, unsubordinated debt and are issued in minimum denominations of $2,000.
AbbVie expects to use the net proceeds primarily to fund a portion of the cash consideration for its pending acquisition of Apogee Therapeutics, Inc. and related fees, and for general corporate purposes, which may include repaying or repurchasing outstanding debt. The Apogee acquisition agreement values Apogee at approximately $10.9 billion.
If AbbVie announces that the Apogee acquisition agreement is terminated or that it will not pursue the transaction, it must redeem specified "Mandatorily Redeemable" series of notes at 101% of principal plus accrued interest under a Special Mandatory Redemption. Other long-dated series are not subject to this feature. The notes are not secured, will not be listed on an exchange, and there is no escrow of offering proceeds for investors’ benefit.
AbbVie delivered strong 2026 mid‑year results, with net revenues of $16,990 million for the quarter and $31,992 million for the first half, up 10% and 11% year over year. Operating earnings reached $6,432 million in Q2 and $10,422 million year‑to‑date, while diluted EPS rose to $2.03 for the quarter and $2.42 for six months.
Growth was led by immunology: Q2 Skyrizi revenues were $5,505 million and Rinvoq $2,525 million, offsetting steep Humira declines. Neuroscience brands including Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev posted broad double‑digit growth, while Imbruvica, Mavyret and parts of the aesthetics portfolio contracted.
Cash flows from operations were $7,265 million, supporting $6,148 million in dividends and $1,498 million of share repurchases, alongside issuance of $8,000 million of new senior notes. AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion and recorded a $650 million upfront payment to RemeGen, reinforcing a pipeline that secured multiple FDA and European approvals across Skyrizi, Rinvoq, Venclexta, Epkinly and aesthetics products.
AbbVie reported strong second‑quarter 2026 results, with net revenues of $16.990 billion, up 10.2 percent on a reported basis, and GAAP diluted EPS of $2.03, up 290.4 percent. Adjusted diluted EPS was $3.65, an increase of 22.9 percent, including a $0.17‑per‑share unfavorable impact from acquired IPR&D and milestones expense. The adjusted operating margin reached 48.3 percent, versus a GAAP operating margin of 37.9 percent.
Growth was led by immunology and neuroscience. Immunology revenues rose to $8.786 billion, driven by Skyrizi at $5.505 billion and Rinvoq at $2.525 billion, while Humira declined to $756 million. Neuroscience revenues grew to $3.228 billion, with Vraylar at $1.071 billion and Botox Therapeutic at $1.042 billion. Oncology revenues were $1.650 billion, modestly lower, as Venclexta grew but Imbruvica declined.
AbbVie also announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in equity value to expand its immunology pipeline. Adjusted diluted EPS guidance for full‑year 2026 was updated from $13.91–$14.11 to $13.87–$14.07, incorporating an expected $0.14‑per‑share dilutive impact from the proposed Apogee acquisition, partially offset by $0.10 of overperformance.
AbbVie Inc. updated its 2026 earnings guidance to reflect second-quarter 2026 acquired IPR&D and milestones expense of $291 million, which is expected to reduce reported GAAP and adjusted non-GAAP diluted EPS by $0.17 per share. The company now expects full-year 2026 adjusted diluted EPS of $13.91–$14.11, compared with previously announced guidance that excluded this second-quarter expense. For the quarter ended June 30, 2026, AbbVie’s adjusted diluted EPS guidance range is $3.57–$3.61, also including the impact of the same $291 million expense. These figures are preliminary and subject to completion of regular financial closing procedures.